Scandinavian ChemoTech’s Animal Care Announces New Partnership

Scandinavian ChemoTech’s is proud to announce a new order secured with a Specialty Animal Care Clinic in Colorado, USA. This new collaboration, valued at approximately USD 40,000, marks another step towards developing the USA market for vetIQure™ and a further achievement in our commitment to advancing veterinary care around the world.

 

Colorado is the 21st largest state in terms of population in the U.S. and ranks 8th in terms of median household income, at USD 82,254. Within the state, approximately 47.2% of households own a pet, which includes a mix of dogs, cats, and other small pets. Colorado is known for being very pet-friendly, and the state tends to have higher rates of pet ownership compared to the national average.[1]

 

Our new partner provides 24-hour emergency veterinary services for dogs and cats. Its experienced medical professionals, many of whom are board-certified specialists, provide pets and their families with a high level of compassionate veterinary specialty and emergency care.  The clinic professional team has added our innovative vetIQure™ TSE system to its facility.

 

Their highly trained team always provide pet owners with education and information they need to make an informed decision about their pet’s health, and will answer any questions owners may have about their pet’s diagnosis.  The addition of the TSE technology to their oncology treatment options will enhance the overall experience at the clinic, offering a unique and patented solution for safe and effective tumour treatment while preserving healthy tissue.

 

"We're excited to broaden the impact of our vetIQure™ TSE system, making it accessible to even more patients and pet owners throughout the United States. Our collaboration with this specialized clinic marks a major milestone for Animal Care’s growth in the Western U.S.” says Danny Nesrallah, Head of Business Development, Animal Care USA.

 

For further information please contact:

Mohan Frick, CEO

 

Phone: +46 (0)10-218 93 00

E-mail: [email protected]

 

 

 

Scandinavian ChemoTech AB (publ)

ChemoTech is a Swedish medical technology company based in Lund that has developed a patented technology platform to offer cancer patients access to a new treatment alternative, Tumour Specific Electroporation™ (TSE), available for treatment of both humans and animals. There are a large number of cancer patients whose tumours for various reasons cannot be treated by conventional methods but where TSE can be a solution. Therefore, the company continuously evaluates new opportunities and areas of application for the technology. ChemoTech's shares (CMOTEC B) are listed on Nasdaq First North Growth Market in Stockholm and Redeye AB is the company's Certified Adviser. Read more at: www.chemotech.se.